Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Unknown 3Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 217OTHER 188NIH 12NETWORK 11OTHER_GOV 5UNKNOWN 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 4Tumor-Agnostic 1

Conditions

Breast Neoplasms 3Neoplasms 1Estrogen Receptor Positive Breast Cancer 1

Interventions

Cisplatin 48Capecitabine 41Gemcitabine 33apatinib 32Oxaliplatin 32Cyclophosphamide 31Radiotherapy 29Paclitaxel 29Carboplatin 29tislelizumab 27Irinotecan 27Drug Therapy 27Fluorouracil 26Docetaxel 26Bevacizumab 23fludarabine 18Nivolumab 17pembrolizumab 16Surgical Procedures, Operative 16Exercise 16Metformin 15S 1 (combination) 14camrelizumab 13Radiation 13Pemetrexed 13Control Groups 12anlotinib 11Leucovorin 11Vinorelbine 10Standard of Care 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × Fulvestrant × Clear all
NCT01992952 2025-11-26

FAKTION

Velindre NHS Trust

Phase 1/2 Active not recruiting
149 enrolled
Breast

Estrogen Receptor Positive Breast Cancer

NCT05176080 2024-12-17

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Henan Cancer Hospital

Phase 1/2 Terminated
46 enrolled
Breast

Breast Neoplasms

NCT05328440 2023-09-25

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Henan Cancer Hospital

Phase 2 Unknown
120 enrolled
Breast

Breast Neoplasms

NCT03024580 2019-08-15

MEGA

Instituto Nacional de Cancer, Brazil

Phase 2 Unknown
20 enrolled
Breast

Breast Neoplasms

NCT02530411 2015-08-21

FURVA

Velindre NHS Trust

Phase 2 Unknown
160 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡